Recruiting

Testing a new medication before eye surgery for uveal melanoma

Plain-English translation of NCT07015190 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called to see if it can help patients with uveal melanoma (a type of eye cancer) before they receive their standard treatment. Half of the participants will receive first, followed by their planned eye treatment, while the other half will go straight to their standard treatment. The study will follow everyone for up to 3 years to see how well the new approach works and how it affects vision and cancer recurrence.

Uveal melanoma is a serious eye cancer, and doctors want to know if giving this medication before standard treatment might help prevent the cancer from coming back or spreading, while also helping patients preserve their vision.

Do you qualify?

You likely qualify if…

you have been diagnosed with primary uveal melanoma that has not spread to other parts of your body
you need either plaque brachytherapy (radiation implant to the eye) or surgical removal of the eye as your planned treatment
you are in good enough health to participate, as confirmed by your doctor
you have adequate organ function and are willing to follow all study requirements for up to 3 years
you have not received any previous treatment for uveal melanoma

You likely don't qualify if…

you have already been treated for uveal melanoma
your cancer has spread to other parts of your body
your eye has other serious disease that would make it difficult to assess vision changes over time
you have another type of cancer besides uveal melanoma
your eye condition requires removal regardless of how you respond to the new medication

What participation looks like

If you join this study, you'll be randomly assigned to either receive followed by your planned eye treatment, or to proceed directly with your standard treatment. You'll have regular clinic visits for examinations, and your vision and cancer status will be carefully monitored over 3 years. The study will track whether the new medication approach helps prevent cancer recurrence and preserves your vision better than standard treatment alone.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(94 sites)

United States

Mayo Clinic Scottsdale - PPDS, Scottsdale, Arizona

UCSD Moores Cancer Center, La Jolla, California

Jules Stein Eye Institute, Los Angeles, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

University of California Irvine Medical Center, Orange, California